483 related articles for article (PubMed ID: 33741584)
1. Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions.
Cabral de Guimaraes TA; Daich Varela M; Georgiou M; Michaelides M
Br J Ophthalmol; 2022 Mar; 106(3):297-304. PubMed ID: 33741584
[TBL] [Abstract][Full Text] [Related]
2. Treatment of dry age-related macular degeneration: A review.
Girgis S; Lee LR
Clin Exp Ophthalmol; 2023 Nov; 51(8):835-852. PubMed ID: 37737509
[TBL] [Abstract][Full Text] [Related]
3. The Role of Inflammation in Age-Related Macular Degeneration-Therapeutic Landscapes in Geographic Atrophy.
Borchert GA; Shamsnajafabadi H; Hu ML; De Silva SR; Downes SM; MacLaren RE; Xue K; Cehajic-Kapetanovic J
Cells; 2023 Aug; 12(16):. PubMed ID: 37626902
[TBL] [Abstract][Full Text] [Related]
4. Recent Developments in the Treatment of Wet Age-related Macular Degeneration.
Papadopoulos Z
Curr Med Sci; 2020 Oct; 40(5):851-857. PubMed ID: 32980899
[TBL] [Abstract][Full Text] [Related]
5. Progression of macular atrophy in patients undergoing anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration.
Cho HJ; Park SM; Kim J; Nah SK; Lee J; Lee DW; Kim JW
Acta Ophthalmol; 2021 Jun; 99(4):e540-e546. PubMed ID: 32996674
[TBL] [Abstract][Full Text] [Related]
6. Disease progression pathways of wet AMD: opportunities for new target discovery.
Wolf AT; Harris A; Oddone F; Siesky B; Verticchio Vercellin A; Ciulla TA
Expert Opin Ther Targets; 2022 Jan; 26(1):5-12. PubMed ID: 35060431
[TBL] [Abstract][Full Text] [Related]
7. Investigational drugs in clinical trials for macular degeneration.
Tolentino MJ; Tolentino AJ
Expert Opin Investig Drugs; 2022 Oct; 31(10):1067-1085. PubMed ID: 35962560
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Options Under Development for Nonneovascular Age-Related Macular Degeneration and Geographic Atrophy.
Kim JB; Lad EM
Drugs Aging; 2021 Jan; 38(1):17-27. PubMed ID: 33355716
[TBL] [Abstract][Full Text] [Related]
9. Age-related macular degeneration therapy: a review.
Ammar MJ; Hsu J; Chiang A; Ho AC; Regillo CD
Curr Opin Ophthalmol; 2020 May; 31(3):215-221. PubMed ID: 32205470
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers for Nonexudative Age-Related Macular Degeneration and Relevance for Clinical Trials: A Systematic Review.
Fang V; Gomez-Caraballo M; Lad EM
Mol Diagn Ther; 2021 Nov; 25(6):691-713. PubMed ID: 34432254
[TBL] [Abstract][Full Text] [Related]
11. Anti-VEGF and Other Novel Therapies for Neovascular Age-Related Macular Degeneration: An Update.
Parravano M; Costanzo E; Scondotto G; Trifirò G; Virgili G
BioDrugs; 2021 Nov; 35(6):673-692. PubMed ID: 34655434
[TBL] [Abstract][Full Text] [Related]
12. Neovascular age-related macular degeneration: potential therapies.
Chappelow AV; Kaiser PK
Drugs; 2008; 68(8):1029-36. PubMed ID: 18484796
[TBL] [Abstract][Full Text] [Related]
13. Anti-VEGF compounds in the treatment of neovascular age related macular degeneration.
Campa C; Harding SP
Curr Drug Targets; 2011 Feb; 12(2):173-81. PubMed ID: 20887245
[TBL] [Abstract][Full Text] [Related]
14. Management of Neovascular Age-related Macular Degeneration: A Review on Landmark Randomized Controlled Trials.
Agarwal A; Aggarwal K; Gupta V
Middle East Afr J Ophthalmol; 2016; 23(1):27-37. PubMed ID: 26957836
[TBL] [Abstract][Full Text] [Related]
15. Vision protection therapy for prevention of neovascular age-related macular degeneration.
Luttrull JK; Gray G; Bhavan SV
Sci Rep; 2023 Oct; 13(1):16710. PubMed ID: 37794027
[TBL] [Abstract][Full Text] [Related]
16. SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration.
Enseleit F; Michels S; Sudano I; Stahel M; Zweifel S; Schlager O; Becker M; Winnik S; Nägele M; Flammer AJ; Neidhart M; Graf N; Matter CM; Seifert B; Lüscher TF; Ruschitzka F
Ophthalmologica; 2017; 238(4):205-216. PubMed ID: 28866675
[TBL] [Abstract][Full Text] [Related]
17. Analysis of choroidal thickness in age-related macular degeneration using spectral-domain optical coherence tomography.
Manjunath V; Goren J; Fujimoto JG; Duker JS
Am J Ophthalmol; 2011 Oct; 152(4):663-8. PubMed ID: 21708378
[TBL] [Abstract][Full Text] [Related]
18. Drugs in Phase II clinical trials for the treatment of age-related macular degeneration.
Tolentino MJ; Dennrick A; John E; Tolentino MS
Expert Opin Investig Drugs; 2015 Feb; 24(2):183-99. PubMed ID: 25243494
[TBL] [Abstract][Full Text] [Related]
19. Age-related macular degeneration: using morphological predictors to modify current treatment protocols.
Ashraf M; Souka A; Adelman RA
Acta Ophthalmol; 2018 Mar; 96(2):120-133. PubMed ID: 29130626
[TBL] [Abstract][Full Text] [Related]
20. Novel and investigational therapies for wet and dry age-related macular degeneration.
Sarkar A; Jayesh Sodha S; Junnuthula V; Kolimi P; Dyawanapelly S
Drug Discov Today; 2022 Aug; 27(8):2322-2332. PubMed ID: 35460893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
